Thymosin beta4 promotes blood vessel formation and stem cell migration

This landmark study, published in Nature, demonstrated for the first time that thymosin beta4 (TB-500) is capable of promoting cardiac repair after ischemic injury in mice. The team led by Nicola Smart at University College London used myocardial infarction models to investigate the regenerative mechanisms mediated by the peptide.

The researchers discovered that thymosin beta4 mobilizes epicardial progenitor cells (EPDCs) and stimulates their migration to the injured myocardium. These progenitor cells, normally quiescent in the adult heart, were reactivated by TB-500 and differentiated into new cardiomyocytes and vascular endothelial cells, promoting neovascularization and regeneration of damaged cardiac tissue.

• Pre-treatment with thymosin beta4 before infarction resulted in smaller infarct size
• New blood vessel formation in the myocardium was significantly increased
• Wt1-positive epicardial cells were identified as the responsive progenitor population
• The mechanism involved signaling via Akt/protein kinase B

Publication in Nature conferred substantial scientific credibility to TB-500, positioning it as one of the most promising peptides for regenerative medicine. The study paved the way for clinical investigations into the use of thymosin beta4 in post-myocardial infarction recovery and other conditions requiring vascular and tissue repair.